UBS Maintains Neutral on Iovance Biotherapeutics, Raises Price Target to $7

Benzinga · 1d ago
UBS analyst David Dai maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Neutral and raises the price target from $4 to $7.